Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 2 · 25%High 4 · 50%

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 31632 participants
High

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28451 participants
High

All‐cause mortalityf

mRNA‐1273 – ModernaTX showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.06 [0.54, 2.1]
1 study · 30346 participants
Low

Systemic reactogenicity events

mRNA‐1273 – ModernaTX leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.28 [1.22, 1.34]
2 studies · 34037 participants
High

Any adverse eventk

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32995 participants
Low

Serious adverse eventsl

mRNA‐1273 – ModernaTX showed no clear difference in serious adverse eventsl compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.78, 1.08]
2 studies · 34072 participants
Moderate

Local reactogenicity events

mRNA‐1273 – ModernaTX leads to higher local reactogenicity eventsi compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 3.3 [2.02, 5.4]
2 studies · 34037 participants
High

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 31632 participants
Moderate